PwPepwise

KPV

Healing & Recovery

α-MSH C-terminal tripeptide

KPV is a naturally occurring tripeptide (lysine-proline-valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH).

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
Topical Ophthalmic (Animal Model)10 mg/mlDailyTopicalApplied on the skin.4 days

Approximate values pulled from the research — double-check before dosing.

§01Summary

KPV is a naturally occurring tripeptide (lysine-proline-valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH), a neuropeptide involved in regulating inflammation and immune responses. As the smallest active fragment of α-MSH, KPV retains potent biological activity in a highly compact form, making it an attractive candidate for targeted therapeutic development.

In preclinical research, KPV has been reported to reduce intestinal inflammation by suppressing key inflammatory signaling pathways at nanomolar concentrations1, with oral and topical formulations showing therapeutic activity in multiple animal models of inflammatory bowel disease1,6. KPV may also support wound healing in mucosal and corneal tissues18,20 and has demonstrated antimicrobial properties against bacterial and fungal pathogens at physiologically relevant concentrations17. A particularly notable feature is its transport via the PepT1 intestinal peptide transporter, which appears to be upregulated in inflamed tissue — potentially enabling disease-targeted delivery1,4. Researchers have actively incorporated KPV into advanced drug delivery systems, including nanoparticles and hydrogels, to improve stability and therapeutic potency5,9,10. While these findings are largely derived from animal and in vitro studies, the evidence base for KPV across inflammatory, mucosal, and antimicrobial indications is actively developing, with growing interest in its translational potential.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment corresponding to residues 11–13 of alpha-melanocyte-stimulating hormone (α-MSH), a tridecapeptide derived from pro-opiomelanocortin (POMC). Despite its minimal size, KPV retains the immunomodulatory capacity of the full-length parent peptide through both receptor-dependent and receptor-independent mechanisms, making it one of the smallest biologically active anti-inflammatory peptides characterized in mammalian systems.

A primary intracellular mechanism involves suppression of the NF-κB and MAP kinase (ERK1/2, JNK, p38) signaling cascades, which reduces transcriptional activation of pro-inflammatory cytokines including IL-1β, TNF-α, IL-6, and IL-81,14. Upstream of these pathways, KPV can signal through the melanocortin-1 receptor (MC-1R) on keratinocytes and antigen-presenting cells, triggering intracellular calcium mobilization rather than the canonical cAMP elevation associated with full-length α-MSH activation8,15. This calcium-dependent signaling has been demonstrated at femtomolar to nanomolar concentrations in human keratinocytes8, and both L- and D-amino acid forms (KP-D-V) appear to retain this activity, suggesting potential for protease-resistant analogs8.

Critically, KPV's anti-inflammatory mechanism in intestinal and leukocyte contexts appears to be largely independent of classical melanocortin receptors. Studies in MC1R-deficient mice demonstrated undiminished efficacy3,6, and in vitro assays confirmed that KPV does not elevate cAMP, does not suppress macrophage-derived KC or IL-1β release via the same pathways as α-MSH, and is unaffected by the MC3/4-R antagonist SHU91193. The most likely alternative mechanism is direct inhibition of IL-1β signaling, positioning KPV as a non-receptor-mediated anti-inflammatory agent with a distinct pharmacological profile from its parent molecule3.

A pharmacokinetically relevant feature is KPV's transport via PepT1 (SLC15A1), a di/tripeptide proton-coupled transporter. PepT1 is constitutively expressed in the small intestinal brush border but is markedly induced in colonic epithelium during inflammatory bowel disease1, and its expression is elevated in human colorectal cancer tissue4. This disease-state upregulation creates a self-targeting delivery mechanism: inflamed colonic tissue preferentially imports KPV, concentrating the peptide at its site of action while minimizing systemic exposure. PepT1-knockout studies confirmed that this transporter is obligatory for KPV's anti-inflammatory and anti-tumorigenic effects in the colon4. KPV also plays a role in wound healing through a nitric oxide-dependent mechanism — topical application to corneal wounds is blocked by the NOS inhibitor L-NAME, linking KPV to NO synthase activation downstream of its receptor engagement20. Additionally, KPV exhibits direct antimicrobial activity against Staphylococcus aureus and Candida albicans partly through cAMP-mediated pathways, while simultaneously enhancing rather than suppressing neutrophil microbicidal function17, providing a dual host-defense profile.

§04Evidence & efficacy

Evidence base
179Studies
41Human
21Animal

KPV has been reported to demonstrate anti-inflammatory efficacy across multiple independent preclinical models and biological systems. In murine colitis models, oral KPV may reduce the incidence and severity of both DSS- and TNBS-induced colitis, supported by improved histology and decreased pro-inflammatory cytokine expression1. These findings have been independently replicated in additional murine DSS and CD45RBhi transfer colitis models, where KPV treatment was associated with faster recovery, greater body weight regain, reduced histological inflammatory infiltrates, and lower colonic myeloperoxidase activity6.

KPV may also attenuate colitis-associated carcinogenesis in wild-type mice subjected to AOM/DSS protocols, with this activity appearing to be PepT1-dependent based on the absence of effect in PepT1-knockout animals4. Advanced delivery formulations have been reported to substantially amplify KPV's preclinical efficacy: nanoparticle encapsulation may provide therapeutic benefit at concentrations approximately 12,000-fold lower than free KPV solution5, and hyaluronic acid-functionalized nanoparticles demonstrated superior mucosal protection and TNF-α downregulation compared to non-functionalized formulations16.

Beyond the gut, topical KPV has been reported to dramatically accelerate corneal epithelial wound healing in rabbits, achieving 100% re-epithelialization by 60 hours versus 0% in placebo controls20. In oral mucositis models, KPV-containing hydrogels may reduce IL-1β and TNF-α while upregulating IL-10, improving functional recovery and demonstrating antibacterial activity against S. aureus and MRSA18.

In vitro, KPV suppresses NF-κB and MAP kinase inflammatory signaling pathways and reduces pro-inflammatory cytokine secretion at nanomolar concentrations in human intestinal epithelial and immune cells1,14, and has been reported to exhibit antimicrobial activity against S. aureus and C. albicans at physiological picomolar concentrations17.

§05Safety

KPV has not been evaluated in registered human clinical trials, and formal human safety data are not yet available. Across preclinical models, KPV has been consistently well-tolerated with no adverse events reported in any of the animal studies reviewed.

In vitro, KPV did not reduce cell viability in intestinal epithelial cells or keratinocytes, and nanoparticle-encapsulated KPV did not affect cell viability or epithelial barrier function in Caco-2 BBE monolayers at tested concentrations5. In corneal epithelial cell cultures, KPV at 1 and 10 µM stimulated rather than reduced cell viability20. KPV-loaded hydrogel systems administered rectally and intracolonically in rat colitis models were well tolerated based on functional recovery metrics such as body weight gain and food intake restoration10,18.

In murine IBD models, oral and systemic KPV treatment produced measurable therapeutic benefit without observable toxicity, including 100% survival in DSS-treated MC1R-deficient mice receiving KPV6. The antimicrobial activity of KPV and α-MSH did not impair neutrophil killing of pathogens in vitro, suggesting the absence of immunosuppressive liability at assessed concentrations17.

KPV is a tripeptide fragment of the endogenous neuropeptide α-MSH, consistent with a favorable endogenous origin safety profile. Advanced delivery systems including PLGA nanoparticles and chitosan/alginate hydrogels were designed to minimize systemic exposure by localizing drug release to inflamed colonic tissue5,7,9.

§06History

KPV was first characterized as the biologically active C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH), a neuropeptide derived from the POMC precursor protein. Research on α-MSH's immunomodulatory properties dates to the early 1990s, with the Lipton and Catania groups establishing α-MSH as a broadly anti-inflammatory neuropeptide. The identification of KPV as a minimal active fragment capable of retaining α-MSH's anti-inflammatory and antimicrobial activities emerged from structure-activity relationship studies that progressively shortened the parent peptide. Early work demonstrated that KPV inhibits S. aureus and Candida albicans at physiological picomolar concentrations and contributes to host defense at mucosal and skin barriers17,19.

A pivotal mechanistic advance came in 2003 when KPV's anti-inflammatory activity was shown to be independent of classical melanocortin receptors, distinguishing it mechanistically from α-MSH3. The same year, broader reviews confirmed that KPV retains MC-1R binding and immunomodulatory capacity comparable to the full tridecapeptide, validating the concept of therapeutic peptide miniaturization15. A landmark 2007 paper in Gastroenterology established the PepT1-mediated delivery mechanism and demonstrated oral efficacy in murine colitis models1, stimulating a sustained research program into advanced colonic delivery systems throughout the 2010s–2020s, including nanoparticle5,16 and hydrogel formulations9,10. The discovery that KPV may prevent colitis-associated carcinogenesis in a PepT1-dependent manner broadened its therapeutic scope4. As of the mid-2020s, KPV is also being explored as a targeting ligand for melanocyte-directed nanoparticle drug delivery in skin diseases11, with human clinical investigation actively developing.

§07References